Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 10Breast Neoplasms 9Prostatic Neoplasms 7Multiple Myeloma 6Colorectal Neoplasms 5Ovarian Neoplasms 4Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Head and Neck Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Recurrence 3Neoplasms, Plasma Cell 3Lung Neoplasms 3Hematologic Neoplasms 3Glioblastoma 3Carcinoma, Ovarian Epithelial 3Urinary Bladder Neoplasms 2Neoplasms by Site 2Mycoses 2Medication Adherence 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Leukemia 2Carcinoma, Transitional Cell 2COVID-19 2Adenocarcinoma 2Uveal Melanoma 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1

Interventions

Fentanyl 13Zoledronic Acid 8Ibandronic Acid 8nabiximols 6Oxycodone 6Tapentadol 5Morphine 4Hydromorphone 4Cryotherapy 4Cryosurgery 4alvimopan 3trimebutine 3-thiocarbamoylbenzenesulfonate 2resiniferatoxin 2cabozantinib 2Tetrodotoxin 2Radiation 2Prednisone 2Naloxone 2Diclofenac 2Analgesics, Opioid 26'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine 2ziconotide 1oxycodone naloxone combination 1imisopasem manganese 1fulranumab 1Xylitol 1Ultracet 1Transdermal Patch 1Therapeutics 1Sufentanil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pain × Standard of Care × Clear all
NCT04572776 2021-11-09

Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain

Sorrento Therapeutics, Inc.

Phase 3 Withdrawn

Cancer Pain, Pain, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡